The DART Trial Evaluates two strategies for delivering ART, comparing: clinical monitoring only with routine laboratory + clinical monitoring structured.

Slides:

Advertisements

Similar presentations

Indicators for monitoring ARV treatment outcomes.

Advertisements

TB/HIV Research Priorities: TB Preventive Therapy.

Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.

Antiretroviral Therapy: An HIV Prevention Strategy? Wafaa El-Sadr, MD, MPH Columbia University Harlem Hospital New York.

Part A/Module A1/Session 4 Part A: Module A1 Session 4 Comprehensive Care for People Living with HIV/AIDS (PLHA)

ARCTIC investigators COI D ISCLOSURE FOR D R. M ONTALESCOT : Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca,

Leading By Example in the Public Health Approach to Antiretroviral Therapy Operations Research Agenda: Innovation & Collaboration What Can Industry Bring.

First-Line HIV Therapy and Treatment Strategies: A Summary of Key CROI 2008 Research First-Line HIV Therapy and Treatment Strategies The Body PRO Coverage.

Atorvastatin in Factorial with Omega-3 fatty acid Risk Reduction in Diabetes …in an academic collaboration with.

Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.

Dixon Chibanda. Background  In sub-Saharan Africa the result of poor adherence to HAART includes poor treatment outcomes and the emergence of virus resistant.

How to Find and Access Clinical Trials New Treatments, No Tricks A Seminar on Minority Participation in Clinical Trials June 15, 2010.

Prevention with Positives; Using Multiple Strategies to Involve Persons Living with HIV in Prevention. TASO Uganda. Emmanuel Odeke,

Yesterday, today, and tomorrow

Morbidity Monitoring Project Data for Resource Planning and Evaluation A.D. McNaghten Centers for Disease Control and Prevention.

Long Term Side Effects of ART in Africa: Third Millenium Dr Cissy Kityo Mutuluuza Joint Clinical Research Centre IAS Conference July.

Welcome Rebecca Wood Chief Executive. Welcome Alzheimer’s Research UK.

HIV and ageing: study aims Aim: to examine the effects of ageing on medical and social outcomes of people living with HIV Example research questions: -

NEVIRAPINE THE CONCERNS REGISTRAR OF MEDICINES 15 AUGUST 2002.

1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.

International Network for the Rational Use of Drugs Initiative on Adherence to Antiretrovirals (INRUD-IAA) Promoting adherence to antiretroviral therapy.

Modified Directly Observed Therapy for First Virologic Failure: ACTG A5234 PI Dr A Chisada Presenter: Dr W Samaneka MBChB, MSc UZ-UCSF ARD 17 April 2015.

C Foster, A Judd, H Lyall, T Dunn, K Doerholt, P Tookey, D Gibb For Young people with perinatally acquired HIV: a Transitioning UK cohort.

Older and wiser: continued improvements in clinical outcome and highly active antiretroviral therapy (HAART) response in HIV-infected children in the UK.

1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.

PV of ARVs Global Picture Dr Paula Munderi WHO Training Course for Introducing Pharmacovigilance of HIV Medicines November 2009, Dar Es Salaam.

Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.

Bridging the gap between research, MCC approval and public access to tenofovir gel Quarraisha Abdool Karim on behalf of the CAPRISA 008 & CAPRISA 009 teams.

Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.

Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao

Raymond F. Anton, MD for The COMBINE Study Research Group

Psychosocial support model for community - based ART initiatives: Zimbabwe experience. Sostain Moyo G.Kadzirange, L. S. Zijenah, T. Kufa. L. Gwanzura,

The Methods for Improving Reproductive Health in Africa (MIRA) Study SOC PROGRAM Liz Montgomery Women’s Global Health Imperative RTI International GCM.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

HIV-infected subjects with CD4 350 to 550 cells/mm serodiscordant couples HPTN 052 Study Design Immediate ART CD Delayed ART CD4

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

What happens when the research is over? Researcher and funder perspectives J Whitworth Head of International Activities Wellcome Trust Global Forum on.

Overview of Microbicide Trials Issues and Challenges.

The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,

Developments in Medical Education Peter Benning Associate Director of Medical Education.

Efficacy of routine viral load, CD4 cell count, and clinical monitoring of adults taking antiretroviral therapy in Rural Uganda Alex Coutinho MD MPH DTM&H.

Module 2: Learning Objectives

Are Patients on HAART in Uganda experiencing less treatment failure than earlier anticipated? A case study of Mbarara JCRC HAART Clinic.

Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,

AN INTERNATIONAL MULTI-CENTRE, RANDOMISED, DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF 0.5% AND 2% PRO 2000 GELS FOR.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.

Adult AIDS Clinical Trials Group International Therapeutic Initiative.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.

OUTCOME OF STAVUDINE INDUCED PERIPHERAL NEUROPATHY IN HIV-1 POSITIVE PATIENTS SWITCHED OR SUBSTITUTED TO A NON-STAVUDINE- BASED REGIMEN Dr P Gorejena-Chidawanyika.

Socioeconomic benefits of ART Decentralization in Malawi and Uganda: Lessons from the Lablite Project Levison Chiwaula, Deborah Ford, Misheck J Nkhata,

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

Building the NIHR NIHR: 10 years of delivering health and care research for the nation QEII Centre, London Wednesday 18 May 2016 Professor Dame Sally C.

ART access in resource limited settings

Drug Development Process Stages involved in Regulating Drugs

CLINICAL TRIALS.

FOGARTY INTERNATIONAL CENTRE AT IAS 50th Anniversary

VESTED Quiz Game

VESTED Quiz Game

Scaling up ART: Joint Clinical Research Centre (JCRC) Experiences

The use of cotrimoxazole prophylaxis in the context of HIV infection

Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Speeding access to therapies

EVALUATION OF ANTIRETROVIRAL THERAPY FOLLOWED BY AN EDUCATIONAL INTERVENTION TO INCREASE APPROPRIATE USE IN ZIMBABWE.

Adele Schwartz Benzaken

Management of Systematic Lupus Erythematosus

Volume 375, Issue 9709, Pages (January 2010)

Volume 375, Issue 9722, Pages (April 2010)

Presentation transcript:

The DART Trial Evaluates two strategies for delivering ART, comparing: clinical monitoring only with routine laboratory + clinical monitoring structured treatment interruptions with continuous ART

Trial features I 5 year trial 3 sites: Harare, Kampala, Entebbe 3000 patients – 1000 at each site / 1 year Primary endpoints : Efficacy -progression to a new WHO stage 4 or death Safety - new SAE which is not HIV related Other outcomes: Adherence, Virological including resistance, Socioeconomic & behavioural impact

DART Entebbe Collaboration with TASO and Entebbe Hospital DART Clinic at Entebbe Hospital – MOH Care services: Counseling Diagnosis of HIV related illness & OIs Treatment of HIV related illness & OIs Antiretroviral therapy & monitoring Psychosocial support

Funding Sources Medical Research Council, UK Rockefeller Foundation, USA Department for International Development, UK Rock House Foundation, UK

Drugs Anti-retroviral drugs donated by Boehringer-Ingelheim- Nevirapine Gilead- Tenofovir GlaxoSmithKline- Combivir

Trial Review Process 2 yrs + Risk benefits fine Most attention to end of trial issues Concern about exclusion of pregnant women ? What happens after patient community Very little discussion on ability of participants to decline

Trial Approval UVRI Science & Ethics Committee Uganda National Council for Science & Technology - granted research clearance Ethics committees in Zimbabwe & UK Support letter from MOH

Trial Monitoring Trial Steering Committee International Co-ordinating Group Local Trial Management Committees Analysis & Data Management Committee Data & Safety Monitoring Committee Pharmaceutical companies - adverse events End Point Review Committee

International Coordinating Group PI’s Dr Peter Mugyenyi - Kampala Prof Jimmy Whittworth - Entebbe Prof Ahmed Latif - Zimbabwe Prof James Hakim - Zimbabwe Prof Janet Darbyshire - London Prof Charles Gilks - Geneva Site investigators Dr Diana Gibb - London Dr Andrew Reid - Zimbabwe Dr Cissy Kityo - Kampala Dr Paula Munderi - Entebbe Plus Dr Dorothy Bray - Consultant Dr Alex Coutinho - TASO Uganda

Other ART Trials in Uganda 1992 JCRC Determining the lowest effective dose of AZT 16 weeks duration 1 yr therapy to participants post trial

Other Trials…………… Care project ( Pharmaccess, GSK, Roche ) Uganda, Kenya, Senegal, Cote d’Ivoire Response, Side effects, Education & adherence 200 participants total, 50 in each country Will provide ART to participants post trial

Other Trials…………… JCRC - NIH Evaluation of short STI strategies ( 7 days on 7 days off / Weekend off ) 171 participants to date Clinical follow up and monitoring provided Patients pay for own ART but save on drug cost ( 50% 7 days ; 30% weekend)